Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$10.48 USD
-0.34 (-3.14%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $10.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Oric Pharmaceuticals, Inc.'s return on equity, or ROE, is -51.75% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ORIC has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ORIC 10.48 -0.34(-3.14%)
Will ORIC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ORIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORIC
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?
Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?
ORIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy
Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
Other News for ORIC
Is ORIC poised for gains? 20 Day Moving Average Support shows up after climbing 2.46%
Oric Pharmaceuticals management to meet virtually with Cantor Fitzgerald
ORIC's price falls by 4.0% on September 19, though its technical setup remains stable.
The technical outlook for ORIC is unchanged after it rises 4.56% on September 18
50 Day Moving Average Support appears for ORIC after 3.49% move